Effects of two structurally diverse positive allosteric modulators on signaling bias at the μ-opioid receptor
- 26 September 2025
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 107 (11) , 100079
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (GM117425, T32 GM140223)
- National Institute on Drug Abuse
- University of Michigan
This publication has 49 references indexed in Scilit:
- Mu Opioid Receptor Positive Allosteric Modulator BMS-986122 Confers Agonist-Dependent G Protein Subtype Signaling BiasBiochemistry, 2025
- Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid AgonistsBiochemistry, 2021
- Critical Assessment of G Protein-Biased Agonism at the μ-Opioid ReceptorTrends in Pharmacological Sciences, 2020
- Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platformBiochemical Pharmacology, 2020
- A Brief History of the Opioid Epidemic and Strategies for Pain MedicinePain and Therapy, 2018
- Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid AnalgesicsCell, 2017
- Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS DisordersNeuron, 2017
- Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid ReceptorJournal of Medicinal Chemistry, 2015
- Distinct pharmacological properties of morphine metabolites at Gi-protein and β-arrestin signaling pathways activated by the human μ-opioid receptorBiochemical Pharmacology, 2011
- Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.The Journal of Pharmacology and Experimental Therapeutics, 1989